AJOG Global Reports (May 2024)

Factors associated with early readmission for postpartum hypertensionAJOG Global Reports at a Glance

  • Katherine Pressman, MD,
  • Jody Wellcome, MD,
  • Chandni Pooran, BS,
  • Daniela Crousillat, MD,
  • Mary A. Cain, MD,
  • Judette M. Louis, MD

Journal volume & issue
Vol. 4, no. 2
p. 100323

Abstract

Read online

BACKGROUND: Hypertensive disorders of pregnancy are increasing in prevalence and a leading cause of early postpartum readmissions. Stricter blood pressure target goals for treatment of hypertension during pregnancy have recently been proposed, however, the treatment goals for management of postpartum hypertension are less well established. OBJECTIVE: We sought to evaluate the clinical factors associated with early postpartum readmissions for hypertensive disease and to evaluate blood pressure thresholds associated with these readmissions. STUDY DESIGN: We conducted a retrospective cohort study of women delivering at a tertiary care center between January 2018 and May 2022 who experienced a hospital readmission for postpartum hypertension or new onset postpartum preeclampsia. Charts were reviewed for clinical and sociodemographic data. Patients with early readmission (1 vitals check during their hospitalization) to be started on antihypertensives before initial delivery discharge; of those 25 (93%) were discharged with a new prescription for an antihypertensive. After controlling for confounding variables, predischarge blood pressure between 130–140 mmHg/80–90 mmHg (adjusted odds ratio, 2.4 [1.5–4.0]) was associated with an increased likelihood of early readmission. CONCLUSION: Patients with delivery for hypertensive disorders of pregnancy and predischarge blood pressure ≥140/90 mmHg were less likely to have an early readmission within 3 days of initial discharge, however, patients with predischarge blood pressure 130–139 mmHg/80–89 mmHg were more likely to have an early readmission for hypertensive disorders of pregnancy and postpartum preeclampsia. Further research is indicated to evaluate interventions to prevent postpartum readmission in patients at high risk for persistent hypertension or new onset postpartum preeclampsia.

Keywords